

# Notice from the Executive Officer: Pan-Canadian Select Molecules Price Initiative for Generic Drugs

May 13, 2022

Ontario has been working with other provincial, territorial and federal drug programs in consultation with pharmaceutical manufacturers on a pan-Canadian initiative to reduce prices for selected generic products.

Effective **May 31, 2022**, the Drug Benefit Prices (DBP) of the following 8 generic molecules on the Ontario Drug Benefit (ODB) Formulary will be further reduced:

- Alendronate
- Atenolol
- Bisoprolol
- Carvedilol
- Dutasteride
- Finasteride
- Risedronate
- Risperidone

The Ministry has posted a new file with the details of the listing changes for download and review (Edition No. 43 Summary of Changes – Pan-Canadian Select Molecules Price Initiative for Generic Drugs – May 2022). It is accessible from the Ministry's website: [http://www.health.gov.on.ca/en/pro/programs/drugs/edition\\_43.aspx](http://www.health.gov.on.ca/en/pro/programs/drugs/edition_43.aspx).

We appreciate your continued cooperation in making these benefit adjustments.